17 August 2020 : Case report
Unusual setting of medical careAlberto Hernández1AE*, Montserrat Viñals2F, Tomas Isidoro3F, Francisco Vilás3E
Am J Case Rep 2020; 21:e925849
BACKGROUND: Pneumonia caused by coronavirus originated in Wuhan, China in late 2019 and has spread around the world, becoming a pandemic. Many patients deteriorate rapidly and require intubation and mechanical ventilation, which is causing the collapse of healthcare systems in many countries. Coronavirus infection is associated with extensive lung inflammation and microvascular thrombosis, which can result in hypoxia. It can also cause severe and lasting harm in other organs, including the heart and kidneys. At present, there is no proven and efficacious treatment for this new disease. Consequently, there is a growing tendency to use novel methods. Ozone therapy consists of administration of a mixture of oxygen and ozone (a molecule consisting of 3 oxygen atoms). The potential benefits of this therapy include reduced tissue hypoxia, decreased hypercoagulability, renal and heart protection, modulated immune function, improved phagocytic function, and impaired viral replication.
CASE REPORT: We report rapidly improved hypoxia with associated decreases in inflammatory markers and D-dimer immediately after 1–4 sessions of oxygen–ozone (O₂–O₃) therapy in 3 patients with COVID-19 pneumonia who presented with respiratory failure. Invasive mechanical ventilation was not required in these 3 patients. All patients were discharged home on days 3–4 after O₂–O₃ therapy.
CONCLUSIONS: O₂–O₃ therapy appears to be an effective therapy for COVID-19 patients with severe respiratory failure. Large controlled clinical trials are required to study the efficacy and safety of using O₂–O₃ therapy compared with the standard supportive case in patients with COVID-19 in terms of the need for invasive ventilation and length of hospital and intensive care unit stays.
Keywords: COVID-19, Ozone, SARS Virus
18 January 2022 : Case reportSickle Cell Trait and SARS-CoV-2-Induced Rhabdomyolysis: A Case Report
Am J Case Rep In Press; DOI: 10.12659/AJCR.934220
11 January 2022 : Case reportMyocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of P...
Am J Case Rep In Press; DOI: 10.12659/AJCR.934399
12 January 2022 : Case reportGuillain-Barré Syndrome After Ad26.COV2.S Vaccination
Am J Case Rep In Press; DOI: 10.12659/AJCR.935275
19 Jan 2022 : Case reportRare Case of Hodgkin Lymphoma Transformation into Diffuse Large B-Cell Lymphoma with Atypical Spread Epidur...
Am J Case Rep In Press; DOI: 10.12659/AJCR.935014
19 Jan 2022 : Case reportAutoimmune Hemolytic Anemia – Rare Complication of Brucellosis in a Saudi Woman: A Case Report and Literatu...
Am J Case Rep In Press; DOI: 10.12659/AJCR.935187
18 Jan 2022 : Case reportAnnular Epidermolytic Ichthyosis Mimicking Greither Disease: A Case Report and Literature Review
Am J Case Rep In Press; DOI: 10.12659/AJCR.935393
Most Viewed Current Articles
10 Jan 2022 : Case reportA Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV...
Am J Case Rep 2022; 23:e935263
06 Dec 2021 : Case reportLipedema Can Be Treated Non-Surgically: A Report of 5 Cases
Am J Case Rep 2021; 22:e934406
24 Jul 2020 : Case reportSymptoms of Pleurisy as the Initial Presentation of COVID-19
Am J Case Rep 2020; 21:e925775